NRIX Quote, Financials, Valuation and Earnings

Amneal Pharmaceuticals has a net margin of -388.91% compared to Nurix Therapeutics's net margin of -0.02%. Nurix Therapeutics's return on equity of -65.52% beat Amneal Pharmaceuticals's return on equity of -587.3%.

Nurix Therapeutics has a consensus price target of $31.65, signalling upside risk potential of 66.19%. On the other hand Amneal Pharmaceuticals has an analysts' consensus of -- which suggests that it could grow by 35.14%. Given that Nurix Therapeutics has higher upside potential than Amneal Pharmaceuticals, analysts believe Nurix Therapeutics is more attractive than Amneal Pharmaceuticals.

Nurix Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Amneal Pharmaceuticals has a beta of 1.102, suggesting its more volatile than the S&P 500 by 10.226%.

Nurix Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Amneal Pharmaceuticals offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics pays -- of its earnings as a dividend. Amneal Pharmaceuticals pays out -- of its earnings as a dividend.

Nurix Therapeutics quarterly revenues are $12.6M, which are smaller than Amneal Pharmaceuticals quarterly revenues of $702.5M. Nurix Therapeutics's net income of -$49M is lower than Amneal Pharmaceuticals's net income of -$156K. Notably, Nurix Therapeutics's price-to-earnings ratio is -- while Amneal Pharmaceuticals's PE ratio is 101.17x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics is 20.84x versus 0.86x for Amneal Pharmaceuticals. Usually stocks with elevated PS ratios are considered overvalued.

KORU Medical Systems has a net margin of -388.91% compared to Nurix Therapeutics's net margin of -19.33%. Nurix Therapeutics's return on equity of -65.52% beat KORU Medical Systems's return on equity of -57.92%.

Nurix Therapeutics has a consensus price target of $31.65, signalling upside risk potential of 66.19%. On the other hand KORU Medical Systems has an analysts' consensus of $4.30 which suggests that it could grow by 22.5%. Given that Nurix Therapeutics has higher upside potential than KORU Medical Systems, analysts believe Nurix Therapeutics is more attractive than KORU Medical Systems.

Nurix Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison KORU Medical Systems has a beta of 0.446, suggesting its less volatile than the S&P 500 by 55.418%.

Nurix Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. KORU Medical Systems offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics pays -- of its earnings as a dividend. KORU Medical Systems pays out -- of its earnings as a dividend.

Nurix Therapeutics quarterly revenues are $12.6M, which are larger than KORU Medical Systems quarterly revenues of $8.2M. Nurix Therapeutics's net income of -$49M is lower than KORU Medical Systems's net income of -$1.6M. Notably, Nurix Therapeutics's price-to-earnings ratio is -- while KORU Medical Systems's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics is 20.84x versus 5.72x for KORU Medical Systems. Usually stocks with elevated PS ratios are considered overvalued.

Schrodinger has a net margin of -388.91% compared to Nurix Therapeutics's net margin of -108.07%. Nurix Therapeutics's return on equity of -65.52% beat Schrodinger's return on equity of -34.83%.

Nurix Therapeutics has a consensus price target of $31.65, signalling upside risk potential of 66.19%. On the other hand Schrodinger has an analysts' consensus of -- which suggests that it could grow by 51.73%. Given that Nurix Therapeutics has higher upside potential than Schrodinger, analysts believe Nurix Therapeutics is more attractive than Schrodinger.

Nurix Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Schrodinger has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Nurix Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Schrodinger offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics pays -- of its earnings as a dividend. Schrodinger pays out -- of its earnings as a dividend.

Nurix Therapeutics quarterly revenues are $12.6M, which are smaller than Schrodinger quarterly revenues of $35.3M. Nurix Therapeutics's net income of -$49M is lower than Schrodinger's net income of -$38.1M. Notably, Nurix Therapeutics's price-to-earnings ratio is -- while Schrodinger's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics is 20.84x versus 7.99x for Schrodinger. Usually stocks with elevated PS ratios are considered overvalued.

Zymeworks has a net margin of -388.91% compared to Nurix Therapeutics's net margin of -186.56%. Nurix Therapeutics's return on equity of -65.52% beat Zymeworks's return on equity of -27.06%.

Nurix Therapeutics has a consensus price target of $31.65, signalling upside risk potential of 66.19%. On the other hand Zymeworks has an analysts' consensus of $20.44 which suggests that it could grow by 41.34%. Given that Nurix Therapeutics has higher upside potential than Zymeworks, analysts believe Nurix Therapeutics is more attractive than Zymeworks.

Nurix Therapeutics has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Zymeworks has a beta of 1.098, suggesting its more volatile than the S&P 500 by 9.809%.

Nurix Therapeutics has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Zymeworks offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Nurix Therapeutics pays -- of its earnings as a dividend. Zymeworks pays out -- of its earnings as a dividend.

Nurix Therapeutics quarterly revenues are $12.6M, which are smaller than Zymeworks quarterly revenues of $16M. Nurix Therapeutics's net income of -$49M is lower than Zymeworks's net income of -$29.9M. Notably, Nurix Therapeutics's price-to-earnings ratio is -- while Zymeworks's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Nurix Therapeutics is 20.84x versus 17.41x for Zymeworks. Usually stocks with elevated PS ratios are considered overvalued.